Search | Page 7 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Therapy for aplastic anemia

    ... in the unrelated donor registry, including cord blood. He is red cell- and platelet transfusion -dependent. He has been recommended therapy with ...

    Research Article last updated 01/09/2012 - 10:58am.

  2. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

    ... more and longer haematological responses and increased red blood cell transfusion independence . Azacitidine prolonged overall survival versus ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Eltrombopag and improved hematopoiesis in refractory aplastic anemia

    ... mimetic eltrombopag (Promacta) can improve blood counts. Twenty-five patients received eltrombopag at a dose of 50 mg, ... were clinically significant changes in blood counts or transfusion independence . Patients with a response continued to receive ...

    Research Article last updated 07/31/2012 - 2:24pm.

  4. Long term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.

    ... Journal Title:  Blood Primary Author:  ... (66%) patients on treatment for over 12 months achieved transfusion independence on eculizumab. The mean transfusion requirement ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies

    ... gene, which impairs the membrane expression on affected blood cells of a number of proteins, including the complement regulators CD55 ... leading to hemoglobin stabilization and transfusion independence in more than half of the patients. However, recent ...

    Research Article last updated 03/05/2013 - 9:38am.

  6. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies

    ... gene, which impairs the membrane expression on affected blood cells of a number of proteins, including the complement regulators CD55 ... leading to hemoglobin stabilization and transfusion independence in more than half of the patients. However, recent ...

    Research Article last updated 10/02/2012 - 9:57am.

  7. Self-perception of symptoms of anemia and fatigue before and after blood transfusions in patients with myelodysplastic syndromes

    ... anemia . Many patients with MDS are dependent on regular blood transfusions. The study aimed to investigate symptoms of anemia and ... in patients with MDS immediately before and after blood transfusion and to capture patients' descriptions of their symptoms. ...

    Research Article last updated 01/20/2015 - 1:01pm.

  8. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

    ... to 20%. Oral and SC azacitidine decreased DNA methylation in blood, with maximum effect at day 15 of each cycle. Hematologic responses ... remission, hematologic improvement, or RBC or platelet transfusion independence) was 35% in previously treated patients and 73% in ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?

    ... Erythropoiesis-stimulating agents (ESA) may reduce red blood cell transfusion requirements. MDS patients receiving ESA were reviewed for ...

    Research Article last updated 12/09/2015 - 8:52am.

  10. Blood Transfusion Safety and Risks

    ... Negative side effects of blood transfusion therapy are uncommon. Blood banks, hospitals, and health-care providers take many precautions to ...

    Page last updated 10/31/2014 - 2:36pm.